GoodRx converts earnings to cash extremely well (692% of net income) at a forward P/E of 10.1x, but revenue is flat to declining, 68% of revenue comes from one product line, insiders sold about $9.7M and the stock trades above the analyst target.
Thesis pillars
- Prescription Transaction Concentration→Stable
- Strong Cash Conversion→Stable
- Flat To Declining Revenue→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Feb 26, 2026
GoodRx Holdings, Inc. (GDRX) Stock Analysis
Breakout setup
Healthcare · Health Information Services
Sell if holding. Analyst target reached at $3.47 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: prescription transactions offering (68.0%).
GoodRx Holdings operates a consumer digital healthcare platform that aggregates prescription pricing from PBMs, pharmacies, and pharma manufacturers, giving U.S. consumers discounted prices via GoodRx codes alongside subscription and telehealth offerings. The company earns... Read more
Sell if holding. Analyst target reached at $3.47 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: prescription transactions offering (68.0%). Chart setup: Golden cross, above all MAs, RSI 56, MACD bullish. Score 4.3/10, moderate confidence.
Passes 3/8 gates (positive momentum, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity and earnings proximity 5d<=7d. Suitability: speculative.
About GoodRx Holdings, Inc.
About GoodRx Holdings, Inc.
GoodRx Holdings' prescription transactions offering, which lets U.S. consumers use GoodRx codes to access PBM-negotiated pharmacy discounts, generated 68% of the company's revenue in 2025, down from 73% in each of the prior two years. The platform processes more than 420 billion pricing data points daily across pharmacy benefit managers, pharmacies, and pharma manufacturers, and in February 2026 GoodRx became an integration partner for pharma manufacturers on the federal TrumpRx.gov discount platform.
GoodRx earns transaction fees from PBMs and partner pharmacies each time a consumer redeems a GoodRx code, plus subscription fees from Gold and RxSmartSaver+ members and advertising and affordability-program fees from pharma manufacturers under the Pharma Direct offering. PBMs supply most of the underlying pricing data, though GoodRx has layered in direct contracts with select pharmacies since 2022 to reduce reliance on any single PBM relationship; the 10-K states no significant PBM has terminated a relationship with the company to date, and several PBM contracts continue to pay GoodRx for consumer activity even after termination. Consumers largely pay cash at the point of sale rather than through commercial or government insurance, a dynamic the company expects to intensify as the 2025 One Big Beautiful Bill Act tightens Medicaid eligibility and shifts more prescription cost burden onto individuals.
Show full overview
GoodRx sits at an inflection point created by federal drug-pricing policy rather than by its own product roadmap. The 10-K discloses that GoodRx became a launch-partner integration for TrumpRx.gov, a government-sponsored direct-to-consumer discount platform some major drug manufacturers joined in February 2026 alongside a renewed push for Most-Favored-Nation pricing, though the company states any effect on its results is unclear and could be significant. That policy shift compounds an existing structural dependence: 68% of 2025 revenue came from the prescription transactions offering, so any migration of consumers or manufacturers toward government-run discount channels could pressure the segment that funds the rest of the platform.
See also: Healthcare · Health Information Services
From GoodRx Holdings, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — GoodRx Holdings, Inc.
Latest news
- NEWS GoodRx Holdings Inc (GDRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey — TradingKey neutral
- NEWS Is GoodRx Holdings Inc (GDRX) Undervalued After Q2 Earnings? EPS - GuruFocus — GuruFocus positive
- NEWS GoodRx (NASDAQ:GDRX) Reports Upbeat Q2 CY2026, Stock Soars - FinancialContent — FinancialContent positive
- NEWS GoodRx (NASDAQ:GDRX) Reports Upbeat Q2 CY2026, Stock Soars - financialcontent.com — financialcontent.com positive
- NEWS GoodRx Holdings, Inc. Revenue Breakdown – NASDAQ:GDRX - TradingView — TradingView neutral
Generated 2026-10-29T11:14:32Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductprescription transactions offering68%10-K Item 1A: 'Revenue from our prescription transactions offering represented 68%, 73%, and 73% of our revenue for the years ended December 31, 2025, 2024, and 2023, respectively.'
Material Events(8-K, last 90d)
- 2026-04-24Item 5.02LOWOn April 23, 2026, the Board appointed Thomas Chan, VP Corporate Controller, as Chief Accounting Officer and principal accounting officer, effective immediately, with a base salary increase to $310,000.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Revenue shrinking — -1.3% YoY. Growth thesis broken unless recovery story develops.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $3.47 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: prescription transactions offering (68.0%). Chart setup: Golden cross, above all MAs, RSI 56, MACD bullish. Prior stop was $3.23. Score 4.3/10, moderate confidence.
Analyst target $3.44 reached (−1.0% from $3.47); no take-profit level is published. Prior stop was $3.23. Stop-loss: $3.23.
Concentration risk — Product: prescription transactions offering (68.0%); Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8).
GoodRx Holdings, Inc. trades at a P/E of 69.4 (forward 9.9). TrendMatrix value score: 6.6/10. Verdict: Sell.
20 analysts cover GDRX with a consensus score of 3.5/5. Average price target: $4.
What does GoodRx Holdings, Inc. do?GoodRx Holdings operates a consumer digital healthcare platform that aggregates prescription pricing from PBMs,...
GoodRx Holdings operates a consumer digital healthcare platform that aggregates prescription pricing from PBMs, pharmacies, and pharma manufacturers, giving U.S. consumers discounted prices via GoodRx codes alongside subscription and telehealth offerings. The company earns transaction fees when consumers redeem GoodRx codes at the pharmacy counter -- prescription transactions represented 68% of 2025 revenue -- plus advertising fees from pharma manufacturers under its Pharma Direct offering.